Relief for Ranbaxy as US GMP woes appear to ease
This article was originally published in Scrip
Executive Summary
Shares of Ranbaxy Laboratories moved up on Indian bourses amid signs that good manufacturing practice (GMP)-related concerns at the firm's US site have eased following the issue by the US FDA of an Establishment Inspection Report (EIR).